HSICHenry Schein, Inc.

Ticker: HSIC | Price: $82.47 | Today's Change: -4.79%

---

What Happened

Henry Schein, Inc. filed an 8-K with the SEC on November 3, 2026 under Items 2.02 and 9.01, disclosing its financial results for the second quarter of fiscal year 2026. Revenue from contracts with customers (excluding assessed tax) came in at $6.41 billion for the quarter, while net income was $196 million. Earnings per share were $1.59 basic and $1.58 diluted for the period, with operating income of $326 million.

---

Why It Matters

The share price is down 4.79% on the day of this report, suggesting the market's immediate reaction to these results has been negative. For investors, the key figures to weigh are:

• Revenue of $6.41B — a substantial top-line figure for the quarter, though context against prior periods is limited by the structured data available in this filing.
• Operating income of $326M — implying an operating margin of approximately 5.1% on reported revenue, which reflects the inherently thin-margin nature of healthcare distribution.
• Net income of $196M and diluted EPS of $1.58 — the bottom-line result that investors and analysts will benchmark against consensus expectations.
• The market reaction suggests the reported figures may have fallen short of investor expectations, though the precise degree of any miss or beat relative to Street consensus is not determinable from the filing data alone.

---

Analysis

Henry Schein operates at the intersection of dental and medical supply distribution and technology-enabled services, a business model that tends to produce relatively steady, if modest, margins. The Q2 FY2026 operating margin of roughly 5.1% is consistent with the company's historically distribution-heavy revenue mix.

The notable intraday decline of nearly 5% signals that at least some portion of the market viewed these results as a disappointment — whether due to the absolute level of revenue, the margin profile, or forward guidance language included in attached exhibits (which are outside the structured XBRL data provided). Investors following this name should pay close attention to any commentary management provided around pricing trends in dental consumables, recovery in specialty products, and the trajectory of its technology and value-added services segment, all of which have been important drivers of profitability in recent periods.

This report follows StockWatch's existing initiating coverage on HSIC. Given the stock's current price of $82.47 and today's move, the gap between the current trading level and our previously published coverage will be of interest to existing followers of the name — readers are encouraged to consult that full coverage for the broader fundamental context.

What to watch next:

• Management commentary and guidance on the earnings call for any updates to full-year revenue or earnings expectations.
• Margin trajectory: whether operating margins are expanding, stable, or compressing versus prior comparable quarters.
• Technology and services mix: any shift in the revenue contribution from higher-margin software and services offerings.
• Market conditions: dental procedure volumes and medical supply demand remain macro-sensitive inputs for HSIC's revenue base.

---

Disclaimer

This report is a news and informational analysis based solely on data contained in Henry Schein's SEC filing and publicly available market data. It does not constitute investment advice, a solicitation to buy or sell any security, or an equity research recommendation. No rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial adviser before making any investment decision.

Existing Coverage

StockWatch has full coverage on HSIC, published 2026-09-17. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-03. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/1000228/000100022826000059/hsic-20261103.htm